Skip to content

Stelis Biopharma receives EIR from the US FDA for Drug-Device Combination Products

The US FDA’s EIR is received for the drug-device combination to be commercialised from the Stelis Pharma#39;s flagship facility in Bengaluru, India

Read More

​ The US FDA’s EIR is received for the drug-device combination to be commercialised from the Stelis Pharma#39;s flagship facility in Bengaluru, India The US FDA’s EIR is received for the drug-device combination to be commercialised from the Stelis Pharma#39;s flagship facility in Bengaluru, India  Moneycontrol Latest News Read More  

Leave a Reply

Your email address will not be published. Required fields are marked *

en_USEnglish